357 related articles for article (PubMed ID: 30894377)
1. CD96 Is an Immune Checkpoint That Regulates CD8
Mittal D; Lepletier A; Madore J; Aguilera AR; Stannard K; Blake SJ; Whitehall VLJ; Liu C; Bettington ML; Takeda K; Long GV; Scolyer RA; Lan R; Siemers N; Korman A; Teng MWL; Johnston RJ; Dougall WC; Smyth MJ
Cancer Immunol Res; 2019 Apr; 7(4):559-571. PubMed ID: 30894377
[TBL] [Abstract][Full Text] [Related]
2. Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer.
Wang Y; Wang C; Qiu J; Qu X; Peng J; Lu C; Zhang M; Zhang M; Qi X; Li G; Hua K
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288463
[TBL] [Abstract][Full Text] [Related]
3. Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy.
Blake SJ; Stannard K; Liu J; Allen S; Yong MC; Mittal D; Aguilera AR; Miles JJ; Lutzky VP; de Andrade LF; Martinet L; Colonna M; Takeda K; Kühnel F; Gurlevik E; Bernhardt G; Teng MW; Smyth MJ
Cancer Discov; 2016 Apr; 6(4):446-59. PubMed ID: 26787820
[TBL] [Abstract][Full Text] [Related]
4. CD96 functions as a co-stimulatory receptor to enhance CD8
Chiang EY; de Almeida PE; de Almeida Nagata DE; Bowles KH; Du X; Chitre AS; Banta KL; Kwon Y; McKenzie B; Mittman S; Cubas R; Anderson KR; Warming S; Grogan JL
Eur J Immunol; 2020 Jun; 50(6):891-902. PubMed ID: 32043568
[TBL] [Abstract][Full Text] [Related]
5. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
Whelan S; Ophir E; Kotturi MF; Levy O; Ganguly S; Leung L; Vaknin I; Kumar S; Dassa L; Hansen K; Bernados D; Murter B; Soni A; Taube JM; Fader AN; Wang TL; Shih IM; White M; Pardoll DM; Liang SC
Cancer Immunol Res; 2019 Feb; 7(2):257-268. PubMed ID: 30659054
[TBL] [Abstract][Full Text] [Related]
6. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
7. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.
Blake SJ; Dougall WC; Miles JJ; Teng MW; Smyth MJ
Clin Cancer Res; 2016 Nov; 22(21):5183-5188. PubMed ID: 27620276
[TBL] [Abstract][Full Text] [Related]
8. BCL9 regulates CD226 and CD96 checkpoints in CD8
Feng M; Wu Z; Zhou Y; Wei Z; Tian E; Mei S; Zhu Y; Liu C; He F; Li H; Xie C; Jin J; Dong J; Yang D; Yu K; Qian J; Lambrechts D; Wang MW; Zhu D
Signal Transduct Target Ther; 2021 Aug; 6(1):313. PubMed ID: 34417435
[TBL] [Abstract][Full Text] [Related]
9. The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells.
Lepletier A; Lutzky VP; Mittal D; Stannard K; Watkins TS; Ratnatunga CN; Smith C; McGuire HM; Kemp RA; Mukhopadhyay P; Waddell N; Smyth MJ; Dougall WC; Miles JJ
Immunol Cell Biol; 2019 Feb; 97(2):152-164. PubMed ID: 30222899
[TBL] [Abstract][Full Text] [Related]
10. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.
Chen C; Guo Q; Fu H; Yu J; Wang L; Sun Y; Zhang J; Duan Y
Biomaterials; 2021 Aug; 275():120988. PubMed ID: 34186238
[TBL] [Abstract][Full Text] [Related]
11. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
[TBL] [Abstract][Full Text] [Related]
12. CD226
Jin HS; Ko M; Choi DS; Kim JH; Lee DH; Kang SH; Kim I; Lee HJ; Choi EK; Kim KP; Yoo C; Park Y
Cancer Immunol Res; 2020 Jul; 8(7):912-925. PubMed ID: 32265229
[TBL] [Abstract][Full Text] [Related]
13. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
[TBL] [Abstract][Full Text] [Related]
14. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.
Ahern E; Harjunpää H; Barkauskas D; Allen S; Takeda K; Yagita H; Wyld D; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2017 Oct; 23(19):5789-5801. PubMed ID: 28634284
[No Abstract] [Full Text] [Related]
15. Fc-Silent Anti-TIGIT Antibodies Potentiate Antitumor Immunity without Depleting Regulatory T Cells.
Piovesan D; de Groot AE; Cho S; Anderson AE; Ray RD; Patnaik A; Foster PG; Mitchell CG; Lopez Espinoza AY; Zhu WS; Stagnaro CE; Singh H; Zhao X; Seitz L; Walker NP; Walters MJ; Sivick KE
Cancer Res; 2024 Jun; 84(12):1978-1995. PubMed ID: 38635895
[TBL] [Abstract][Full Text] [Related]
16. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
[TBL] [Abstract][Full Text] [Related]
17. TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer.
Maas RJ; Hoogstad-van Evert JS; Van der Meer JM; Mekers V; Rezaeifard S; Korman AJ; de Jonge PK; Cany J; Woestenenk R; Schaap NP; Massuger LF; Jansen JH; Hobo W; Dolstra H
Oncoimmunology; 2020 Nov; 9(1):1843247. PubMed ID: 33224630
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
[TBL] [Abstract][Full Text] [Related]
19.
Wang B; Zhang W; Jankovic V; Golubov J; Poon P; Oswald EM; Gurer C; Wei J; Ramos I; Wu Q; Waite J; Ni M; Adler C; Wei Y; Macdonald L; Rowlands T; Brydges S; Siao J; Poueymirou W; MacDonald D; Yancopoulos GD; Sleeman MA; Murphy AJ; Skokos D
Sci Immunol; 2018 Nov; 3(29):. PubMed ID: 30389797
[TBL] [Abstract][Full Text] [Related]
20. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
